Market Overview:
The global lurasidone hydrochloride API market is expected to grow at a CAGR of XX% and reach a value of USD XX million by 2030. The market is segmented on the basis of type, application and region.
Product Definition:
Lurasidone hydrochloride is an antipsychotic agent used in the treatment of schizophrenia and bipolar disorder. It is a second-generation antipsychotic that exhibits high affinity for serotonin 5HT2A and dopamine D2 receptors.
Purity≥98%:
Lurasidone Hydrochloride is a prescription drug used for the treatment of Parkinson's disease. It was developed by GlaxoSmithKline as a non-competitive inhibitor of Dopamine Receptor (DR). The drug has an excellent safety and efficacy record and is marketed in Europe as well as Japan. However, it failed to gain approval from the U.
Purity
Lurasidone Hydrochloride is a prescription drug used for the treatment of schizophrenia. It works by altering the way information is processed in the brain. According to research, it has been found that around 1% of people living in North America, Europe, and Australia are suffering from schizophrenia. The high prevalence rate coupled with growing awareness about mental disorders among general population has led to an increase in demand for effective medicines such as Lurasidone Hydrochloride over the past few years.
Application Insights:
Rivaroxaban tablets were the most prominent application segment and accounted for a revenue share of around 40.0% in 2017. The product is used as an alternative to other anti-depressants, which has led to its increased demand in clinical settings over the past few years. Furthermore, growing awareness about mental health issues and increasing availability of treatment options are expected to drive lurasidone hydrochloride API market growth over the forecast period.
The others segment includes products such as trifluoperazine maleate, Stavzor (mefloquine), Minalax (misoprostol), Lomotil (thiamylal) and many more; however, rivaroxaban tablets are anticipated to remain dominant throughout the forecast period owing to extensive usage coupled with high patient awareness regarding depression across various regions globally.
Regional Analysis:
Asia Pacific led the global market in 2017 and is anticipated to continue its dominance over the forecast period. This can be attributed to increasing product demand for treating Alzheimer’s disease, Parkinson's disease, epilepsy and bipolar disorder. China is one of the largest markets in this region owing to factors such as growing healthcare expenditure, rising geriatric population prone to mental disorders coupled with improving healthcare infrastructure. In addition, high unmet clinical needs are expected to drive lurasidone hydrochloride API market growth over the forecast period.
Europe accounted for a significant share of revenue in 2017 due to presence of key manufacturers such as Roerig GmbH & Co., Ltd., FrieslandCampina-Conagra Ltd.
Growth Factors:
- Increasing prevalence of mental disorders: The global prevalence of mental disorders is increasing at an alarming rate. According to the World Health Organization (WHO), around 450 million people suffer from some form of mental disorder. This number is expected to reach 615 million by 2030. This growing population is expected to drive the demand for lurasidone hydrochloride API in the coming years.
- Rising awareness about mental health: There is a growing awareness about the importance of mental health and its impact on overall well-being among people across the world. This has led to an increase in demand for treatments for various forms of mental illness, which in turn is driving growth in the lurasidone hydrochloride API market.
- Growing geriatric population: The geriatric population (aged 65 years or above) is growing at a rapid pace across the world due to advances in healthcare and lifestyle changes such as increased life expectancy and declining fertility rates .This trend is expected to fuel demand for lurasidone hydrochloride API over the next few years, as this drug class has been found effective in treating various psychiatric conditions prevalent among elderly patients .
Scope Of The Report
Report Attributes
Report Details
Report Title
Lurasidone Hydrochloride API Market Research Report
By Type
Purity≥98%, Purity<98%
By Application
Rivaroxaban Tablets, Others
By Companies
Dr. Reddy's Laboratories, Actis Generics Pvt Ltd., ZCL Chemicals Limited, Medichem S.A, UQUIFA, Inke, Teva Pharmaceutical Industries Ltd., Zhejiang Huahai Pharmaceutial. Co., Ltd., Morepen Labs, Shaanxi Hanjiang Pharmaceutical, Jiangsu Jiayi, Shanghai Haoyuan, Nanjing Hicin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Lurasidone Hydrochloride API Market Report Segments:
The global Lurasidone Hydrochloride API market is segmented on the basis of:
Types
Purity≥98%, Purity<98%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rivaroxaban Tablets, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Reddy's Laboratories
- Actis Generics Pvt Ltd.
- ZCL Chemicals Limited
- Medichem S.A
- UQUIFA
- Inke
- Teva Pharmaceutical Industries Ltd.
- Zhejiang Huahai Pharmaceutial. Co., Ltd.
- Morepen Labs
- Shaanxi Hanjiang Pharmaceutical
- Jiangsu Jiayi
- Shanghai Haoyuan
- Nanjing Hicin
Highlights of The Lurasidone Hydrochloride API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity≥98%
- Purity<98%
- By Application:
- Rivaroxaban Tablets
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lurasidone Hydrochloride API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lurasidone Hydrochloride API is a prescription medication used to treat major depressive disorder (MDD). It works by restoring the balance of serotonin and norepinephrine in the brain.
Some of the major companies in the lurasidone hydrochloride api market are Dr. Reddy's Laboratories, Actis Generics Pvt Ltd., ZCL Chemicals Limited, Medichem S.A, UQUIFA, Inke, Teva Pharmaceutical Industries Ltd., Zhejiang Huahai Pharmaceutial. Co., Ltd., Morepen Labs, Shaanxi Hanjiang Pharmaceutical, Jiangsu Jiayi, Shanghai Haoyuan, Nanjing Hicin.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lurasidone Hydrochloride API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lurasidone Hydrochloride API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lurasidone Hydrochloride API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lurasidone Hydrochloride API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lurasidone Hydrochloride API Market Size & Forecast, 2020-2028
4.5.1 Lurasidone Hydrochloride API Market Size and Y-o-Y Growth
4.5.2 Lurasidone Hydrochloride API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Purity≥98%
5.2.2 Purity<98%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Rivaroxaban Tablets
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lurasidone Hydrochloride API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lurasidone Hydrochloride API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Purity≥98%
9.6.2 Purity<98%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Rivaroxaban Tablets
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Purity≥98%
10.6.2 Purity<98%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Rivaroxaban Tablets
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Purity≥98%
11.6.2 Purity<98%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Rivaroxaban Tablets
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Purity≥98%
12.6.2 Purity<98%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Rivaroxaban Tablets
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Purity≥98%
13.6.2 Purity<98%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Rivaroxaban Tablets
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lurasidone Hydrochloride API Market: Competitive Dashboard
14.2 Global Lurasidone Hydrochloride API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Reddy's Laboratories
14.3.2 Actis Generics Pvt Ltd.
14.3.3 ZCL Chemicals Limited
14.3.4 Medichem S.A
14.3.5 UQUIFA
14.3.6 Inke
14.3.7 Teva Pharmaceutical Industries Ltd.
14.3.8 Zhejiang Huahai Pharmaceutial. Co., Ltd.
14.3.9 Morepen Labs
14.3.10 Shaanxi Hanjiang Pharmaceutical
14.3.11 Jiangsu Jiayi
14.3.12 Shanghai Haoyuan
14.3.13 Nanjing Hicin
